In Vivo High Throughput Screening

Scaling up drug discovery in orders of magnitude

Out of every 10,000 compounds, only one reaches the market1.

Most fail due to a lack of efficacy or unexpected toxicity, leading to years of lost time and millions in wasted investment.

Typical Drug Discovery Pathway

At Magnitude Biosciences, we’re transforming the early stages of drug discovery by providing rapid, scalable in vivo screening using C. elegans.

Our patented technology allows us to screen drug libraries from $1 per compound, giving you whole organism readouts in weeks, reducing R&D costs and time to market.

Combining the power of C. elegans and the WormGazer® to solve the challenges of Drug Discovery

Challenge

Solution

High Costs

Screen drug libraries in-vivo for as little as £1 per compound

Long Timelines

In-vivo lifespan reports in weeks, not years

In vitro limitations

Utilise the significant transability of C. elegans to find more hits and leads reliably

In vivo limitations

No regulatory requirements, faster and cheaper.

Accelerating the Drug Discovery Pipeline with C. elegans

Why use C. elegans for Drug Discovery?

Scientific Value: An established, predictive model that’s won four Nobel Prizes, C. elegans is a proven tool for biomedical research.

Human Translatability: With 60–80% gene conservation and high homology to human proteins and cellular pathways, C. elegans provides valuable insights relevant to human biology.

Speed & Cost Efficiency: A rapid 2–3 week lifespan enables faster results compared to rodent studies, delivering whole-organism data at a fraction of the cost.

Scalability: Our WormGazer® platform supports high-throughput testing with C. elegans, making it ideal for screening thousands of compounds.

Regulatory & Ethical Compliance: No regulatory restrictions or ethical concerns, fully 3R-compliant, and highly sustainable.

Unlike in vitro models, C. elegans allows you to understand drug effects in a naturally aging, whole-organism in vivo system, providing more reliable, translatable results.

Average Timeline of Pre-Clinical Models

Our Screening Platforms
Three levels of screening designed to meet your specific needs:

High Throughput 

Medium Throughput

In-depth Characterisation

Platform

Automated imaging in mini liquid wells

Continuous automated imaging in mini agar wells

Continuous automated imaging on agar plates

Readout

Alive vs dead, 1-10 time points for data collection

Multi-endpoint health data at specific ages

Multi-endpoint health data from all life stages

Scale

Rapid screening of 100,000+ compounds

Rich data for prioritisation of 100-10,000 compounds 

Our deepest insights for 1-100 compounds

Cost

$1 – 10 per compound

$50-$300 per compound

$4,000 per compound

Speed

From 1 day*

up to 7 days*

7 days*

Estimate the cost of your project:

Select Screening Type(s)
Name
This field is for validation purposes and should be left unchanged.

The Advantages of High Throughput Screening Powered By C. elegans & WormGazer®

Cost-Effective: Maximise data, from just $1 a compound

Scalable Automation: Screen 100,000s of compounds 

Rapid Turnaround: Actionable data in 7 days

In Vivo Accuracy: Highly translatable efficacy and tox data

Regulation-Free Testing: 3R compliant ethical model

We have different WormGazer® platforms to suit the throughput you need from 10s to 1,000,000s

Sliding scale price range from $1 to $4,000 per compound depending on the richness of data and the rate of compound attrition you need

We offer multiple entry points for your compounds throughout the development pipeline

Or combine our platforms for an end-to-end service from screening to lead candidates ID

Why Magnitude Biosciences?

We take a hands on and collaborative approach to our projects, offering support from study design to data interpretation and presentation.

Over 80+ years
C. elegans experience

Over 100 projects completed

Multidisciplinary team

Get in touch today to find out how we can support you to accelerate your research

Privacy Policy
This field is for validation purposes and should be left unchanged.

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news